MAPT and tauopathy: Passive immunotherapy approaches targeting pathological tau with a variety of linear-epitope and phospho-tau mAbs have also shown efficacy in multiple tauopathy mouse models [28, 30–38, 43], as have some active immunization approaches [62, 63].